Poseida Therapeutics Appoints Catherine J. Mackey, Ph.D and Marcea Bland Lloyd, J.D as Independent Directors
January 04, 2019 at 04:53 pm EST
Share
Poseida Therapeutics Inc. announced the expansion of its board of directors with the appointment of Catherine J. Mackey, Ph.D., who will chair Poseida’s compensation committee, and Marcea Bland Lloyd, J.D., who will chair the nominating and governance committee. Dr. Mackey brings more than 30 years of operating experience in the pharmaceutical and biotechnology sectors. She is currently CEO of CYPrus Therapeutics, chairman of the board of directors of Cour Pharmaceutical Development, and a member of the board of directors of GW Pharmaceuticals as well as Rady Children’s Hospital. Dr. Mackey formerly served as senior vice president of worldwide research and development at Pfizer Inc., where she built Pfizer La Jolla into a primary pharmaceutical research and development site, with over 1,000 employees and a robust drug pipeline. Marcea Bland Lloyd, J.D., has more than 40 years of executive management, operational and legal experience, predominantly in healthcare. She served as chief administrative officer and general counsel of Amylin Pharmaceuticals, prior to the company’s acquisition by Bristol-Myers Squibb. She also served as group senior vice president, chief administrative officer, general counsel and secretary of VHA Inc., a national health care network and spent many years with Medtronic in legal roles including assistant general counsel. Ms. Lloyd is past chairperson of the Executive Leadership Foundation, a former member of the board of directors for California Healthcare Institute and a former associate of the Women Business Leaders of the United States Health Care Industry Foundation.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
POSEIDA THERAPEUTICS, INC. 
